WO2023174897A1 - Composition comprenant un anticorps se liant à srrm2 humain présent sur la surface cellulaire d'une cellule cible - Google Patents

Composition comprenant un anticorps se liant à srrm2 humain présent sur la surface cellulaire d'une cellule cible Download PDF

Info

Publication number
WO2023174897A1
WO2023174897A1 PCT/EP2023/056397 EP2023056397W WO2023174897A1 WO 2023174897 A1 WO2023174897 A1 WO 2023174897A1 EP 2023056397 W EP2023056397 W EP 2023056397W WO 2023174897 A1 WO2023174897 A1 WO 2023174897A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
acid sequence
seq
antibody
set forth
Prior art date
Application number
PCT/EP2023/056397
Other languages
English (en)
Inventor
Reinhard Zeidler
Kathrin GAERTNER
Original Assignee
Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh)
Eximmium Biotechnologies Gmbh
Klinikum Der Universitaet Muenchen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh), Eximmium Biotechnologies Gmbh, Klinikum Der Universitaet Muenchen filed Critical Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh)
Publication of WO2023174897A1 publication Critical patent/WO2023174897A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Abstract

La présente invention concerne une composition pharmaceutique comprenant un anticorps qui se lie à SRRM2 humain présent sur la surface cellulaire d'une cellule cible et éventuellement un véhicule, un diluant ou un excipient de qualité pharmaceutique. La présente invention concerne en outre ladite composition pharmaceutique destinée à être utilisée dans une méthode de traitement du cancer chez un sujet humain. L'invention concerne en outre une méthode permettant de déterminer si un sujet humain est susceptible de souffrir d'un cancer, consistant à déterminer dans un échantillon obtenu dudit sujet humain si SRRM2 est présent sur la surface cellulaire de cellules prélevées contenues dans ledit échantillon. De plus, un anticorps, qui se lie à SRRM2 humain présent sur la surface cellulaire d'une cellule cible, est utilisé et un anticorps, qui se lie à SRRM2 humain présent sur la surface cellulaire d'une cellule cible destiné à une utilisation dans une méthode de destruction de ladite cellule cible ayant SRRM2 humain présent sur la surface cellulaire.
PCT/EP2023/056397 2022-03-14 2023-03-14 Composition comprenant un anticorps se liant à srrm2 humain présent sur la surface cellulaire d'une cellule cible WO2023174897A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22161839 2022-03-14
EP22161839.0 2022-03-14

Publications (1)

Publication Number Publication Date
WO2023174897A1 true WO2023174897A1 (fr) 2023-09-21

Family

ID=80738871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/056397 WO2023174897A1 (fr) 2022-03-14 2023-03-14 Composition comprenant un anticorps se liant à srrm2 humain présent sur la surface cellulaire d'une cellule cible

Country Status (1)

Country Link
WO (1) WO2023174897A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2202245A1 (fr) * 2007-09-26 2010-06-30 Chugai Seiyaku Kabushiki Kaisha Procédé permettant de modifier le point isoélectrique d'un anticorps par substitution d'acide aminé dans une région déterminant la complémentarité (cdr)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2202245A1 (fr) * 2007-09-26 2010-06-30 Chugai Seiyaku Kabushiki Kaisha Procédé permettant de modifier le point isoélectrique d'un anticorps par substitution d'acide aminé dans une région déterminant la complémentarité (cdr)

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN KELLNER ET AL: "Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy", TRANSFUSION MEDICINE HEMOTHERAPY, vol. 44, no. 5, 1 January 2017 (2017-01-01), CH, pages 327 - 336, XP055612043, ISSN: 1660-3796, DOI: 10.1159/000479980 *
GIULIO CASI ET AL: "Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer", JOURNAL OF MEDICINAL CHEMISTRY, vol. 58, no. 22, 23 July 2015 (2015-07-23), US, pages 8751 - 8761, XP055473740, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.5b00457 *
ILIK IBRAHIM AVSAR ET AL: "SON and SRRM2 are essential for nuclear speckle formation", ELIFE, vol. 9, 23 October 2020 (2020-10-23), XP055949740, DOI: 10.7554/eLife.60579 *
KLICHINSKY MICHAEL ET AL: "Human chimeric antigen receptor macrophages for cancer immunotherapy", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 38, no. 8, 23 March 2020 (2020-03-23), pages 947 - 953, XP037211712, ISSN: 1087-0156, [retrieved on 20200323], DOI: 10.1038/S41587-020-0462-Y *
LEGARTOVÁ SONA ET AL: "The SC-35 Splicing Factor Interacts with RNA Pol II and A-Type Lamin Depletion Weakens This Interaction", CELLS, vol. 10, no. 2, 1 January 2021 (2021-01-01), pages 297, XP093000167, DOI: 10.3390/cells10020297 *
MCKAY BROWN ET AL: "Tolerance to single, but not multiple, amino acid replacements in antibody V-H CDR2: A means of minimizing B cell wastage from somatic hypermutation?", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, vol. 156, no. 9, 1 January 1996 (1996-01-01), pages 3285 - 3291, XP002649029, ISSN: 0022-1767 *
ROHTESH S. MEHTA ET AL: "Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer", FRONTIERS IN IMMUNOLOGY, vol. 9, 1 February 2018 (2018-02-01), pages 283, XP055681692, DOI: 10.3389/fimmu.2018.00283 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *
TANAKA HIKARI ET AL: "The intellectual disability gene PQBP1 rescues Alzheimer's disease pathology", MOLECULAR PSYCHIATRY, NATURE PUBLISHING GROUP UK, LONDON, vol. 23, no. 10, 3 October 2018 (2018-10-03), pages 2090 - 2110, XP036800633, ISSN: 1359-4184, [retrieved on 20181003], DOI: 10.1038/S41380-018-0253-8 *
TEOH PHAIK JU ET AL: "CAR T-cell therapy in multiple myeloma: more room for improvement", BLOOD CANCER JOURNAL, vol. 11, no. 4, 1 April 2021 (2021-04-01), pages 84, XP055950065, DOI: 10.1038/s41408-021-00469-5 *
ULRICH WEIDLE ET AL: "Intracellular Proteins Displayed on the Surface of Tumor Cells as Targets for Therapeutic Intervention with Antibody-related Agents", CANCER GENOMICS & PROTEOMICS, vol. 8, 21 March 2011 (2011-03-21), pages 49 - 64, XP055414016 *
XU SHAOHAI ET AL: "SRRM2 organizes splicing condensates to regulate alternative splicing", BIORXIV, 4 July 2022 (2022-07-04), pages 1 - 46, XP055950296, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2022.07.04.498628v1.full.pdf> [retrieved on 20220809], DOI: 10.1101/2022.07.04.498628 *

Similar Documents

Publication Publication Date Title
JP7455787B2 (ja) グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
JP6936784B2 (ja) グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法
EP2096122B1 (fr) Anticorps anti-humain specifiques de dlk1 presentant une activite anti-tumorale in vivo
EP2275537B1 (fr) Anticorps anti-humain spécifiques de dlk1 présentant une activité anti-tumorale in vivo
KR102149565B1 (ko) in vivo 에서 항종양 활성을 갖는 항인간 Dlk-1 항체
CN116323676A (zh) 抗Claudin18.2和CD3的双特异性抗体以及其用途
US7396915B2 (en) Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
US20180002439A1 (en) Anti-mesothelin antibodies and uses thereof
JP2022062018A (ja) ポドカリキシン及びｔｒａ関連抗体、調製方法、並びに抗癌治療剤としての使用
CN115943162A (zh) 抗Claudin18.2抗体以及其用途
TW202402805A (zh) 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法
WO2023174897A1 (fr) Composition comprenant un anticorps se liant à srrm2 humain présent sur la surface cellulaire d&#39;une cellule cible
US20240050475A1 (en) Composition comprising an antibody which binds to human prdx4 present on the cell surface of a target cell
US9273140B2 (en) Antibody for detecting DNA damage in cells utilizing cell membrane surface antigen Ly6D
CN116981688A (zh) 包含结合存在于靶细胞的细胞表面上的人prdx4的抗体的组合物
RU2774710C2 (ru) Антитело против подокаликсина и tra-родственного белка, способы его получения и применения в качестве противоопухолевого терапевтического средства
WO2023190465A1 (fr) Anticorps anti-sema7a humain
JP2005040126A (ja) モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬
CN117597362A (zh) 抗紧密连接蛋白-6的抗体及其用途
WO2023175117A1 (fr) Anticorps dirigés contre lypd3
JP2024508304A (ja) Ｃｌａｕｄｉｎ－６に対する抗体およびそれの使用
CN117720660A (zh) 抗人鸟苷酸环化酶c抗体及其试剂盒和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23715415

Country of ref document: EP

Kind code of ref document: A1